PharmacoEconomics

, Volume 27, Issue 11, pp 903–917 | Cite as

Cost Effectiveness in Low- and Middle-Income Countries

A Review of the Debates Surrounding Decision Rules
  • Samuel D. Shillcutt
  • Damian G. Walker
  • Catherine A. Goodman
  • Anne J. Mills
Review Article Cost-Effectiveness Decision Rules

Abstract

Cost-effectiveness analysis (CEA) is increasingly important in public health decision making, including in low- and middle-income countries. The decision makers’ valuation of a unit of health gain, or ceiling ratio (λ), is important in CEA as the relative value against which acceptability is defined, although values are usually chosen arbitrarily in practice. Reference case estimates for λ are useful to promote consistency, facilitate new developments in decision analysis, compare estimates against benefit-cost ratios from other economic sectors, and explicitly inform decisions about equity in global health budgets.

The aim of this article is to discuss values for λ used in practice, including derivation based on affordability expectations (such as $US150 per disabilityadjusted life-year [DALY]), some multiple of gross national income or gross domestic product, and preference-elicitation methods, and explore the implications associated with each approach. The background to the debate is introduced, the theoretical bases of current values are reviewed, and examples are given of their application in practice. Advantages and disadvantages of each method for defining λ are outlined, followed by an exploration of methodological and policy implications.

Notes

Acknowledgements

No specific sources of funding were used to assist in the preparation of this review. Samuel Shillcutt is supported by the WHO Child Health Epidemiology Reference Group (CHERG), Damian Walker is supported by the UK Department for International Development (DFID)-funded Future Health Systems Consortium, and Catherine Goodman is a member of the KEMRI/Wellcome Trust Research Programme, which is supported by a grant from the Wellcome Trust (#077092). The authors have no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Warner KE, Hutton RC. Cost-benefit and cost-effectiveness analysis in health care: growth and composition of the literature. Med Care 1980; 18 (11): 1069–84PubMedCrossRefGoogle Scholar
  2. 2.
    Elixhauser A, Luce BR, Taylor WR, et al. Health care CBA/CEA: an update on the growth and composition of the literature. Med Care 1993; 31 Suppl. 7: JS1–11, JS8-149Google Scholar
  3. 3.
    Elixhauser A, Halpern M, Schmier J, et al. Health care CBA and CEA from 1991 to 1996: an updated bibliography. Med Care 1998; 36 Suppl. 5: MS1–9, MS18-147Google Scholar
  4. 4.
    Walker D, Fox-Rushby JA. Economic evaluation of communicable disease interventions in developing countries: a critical review of the published literature. Health Econ 2000; 9 (8): 681–98PubMedCrossRefGoogle Scholar
  5. 5.
    Adam T, Lim SS, Mehta S, et al. Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries. BMJ 2005; 331 (7525): 1107PubMedCrossRefGoogle Scholar
  6. 6.
    Mulligan JA, Walker D, Fox-Rushby JA. Economic evaluations of non-communicable disease interventions in developing countries: a critical review of the evidence base. Cost Eff Resour Alloc 2006; 4: 7PubMedCrossRefGoogle Scholar
  7. 7.
    Baltussen R, Floyd K, Dye C. Cost effectiveness analysis of strategies for tuberculosis control in developing countries. BMJ 2005; 331 (7529): 1364PubMedCrossRefGoogle Scholar
  8. 8.
    Chisholm D. Cost-effectiveness of first-line antiepileptic drug treatments in the developing world: a populationlevel analysis. Epilepsia 2005; 46 (5): 751–9PubMedCrossRefGoogle Scholar
  9. 9.
    Chisholm D, Rehm J, Van Ommeren M, et al. Reducing the global burden of hazardous alcohol use: a comparative cost-effectiveness analysis. J Stud Alcohol 2004; 65 (6): 782–94PubMedGoogle Scholar
  10. 10.
    Chisholm D. Choosing cost-effective interventions in psychiatry: results from the CHOICE programme of the World Health Organization. World Psychiatry 2005; 4 (1): 37–44PubMedGoogle Scholar
  11. 11.
    Chisholm D, van Ommeren M, Ayuso-Mateos JL, et al. Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder. Br J Psychiatry 2005; 187 (6): 559–67PubMedCrossRefGoogle Scholar
  12. 12.
    Tan-Torres Edejer T, Baltussen R, Adam T, et al. WHO guide to cost-effectiveness analysis. Geneva: WHO, 2003Google Scholar
  13. 13.
    Hogan DR, Baltussen R, Hayashi C, et al. Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. BMJ 2005; 331 (7530): 1431–7PubMedCrossRefGoogle Scholar
  14. 14.
    Morel CM, Lauer JA, Evans DB. Cost effectiveness analysis of strategies to combat malaria in developing countries [published erratum appears in BMJ 2006; 332 (7534): 151 and BMJ 2006; 333 (7558): 86]. BMJ 2005; 331 (7528): 1299PubMedCrossRefGoogle Scholar
  15. 15.
    Shibuya K, Ciecierski C, Guindon E, et al. WHO Framework Convention on Tobacco Control: development of an evidence based global public health treaty. BMJ 2003; 327 (7407): 154–7PubMedCrossRefGoogle Scholar
  16. 16.
    Jamison DT, Mosley WH, Measham AR, et al. Disease control priorities in developing countries. Oxford: Oxford University Press, 1993Google Scholar
  17. 17.
    World Bank. World development report. Washington, DC: World Bank, 1993Google Scholar
  18. 18.
    WHO-CHOICE. Choosing interventions that are costeffective [online]. Available from URL: (http://www.who.int/choice/en) [Accessed 2006 Jun 30]
  19. 19.
    Jamison D, Breman J, Measham A, et al. Disease control priorities in developing countries. 2nd ed. Washington, DC: The World Bank and Oxford University Press, 2006Google Scholar
  20. 20.
    Lomborg B. Copenhagen Consensus [online]. Available from URL: (http://www.copenhagenconsensus.com/Home-1.aspx) [Accessed 2009 Jan 13]
  21. 21.
    Musgrove P. Public spending on health care: how are different criteria related? Health Policy 1999; 47: 207–23PubMedCrossRefGoogle Scholar
  22. 22.
    Musgrove P. A critical review of ‘a critical review’: the methodology of the 1993 World Development Report, ‘Investing in Health’. Health Policy Plan 2000; 15 (1): 110–5PubMedCrossRefGoogle Scholar
  23. 23.
    Musgrove P, Fox-Rushby J. Cost-effectiveness analysis. In: Jamison D, Breman J, Measham A, et al., editors. Disease control priorities in developing countries. 2nd ed. Washington, DC: The World Bank and Oxford University Press, 2006Google Scholar
  24. 24.
    Briggs AH. Handling uncertainty in economic evaluation and presenting the results. In: Drummond MF, McGuire A, editors. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press, 2001: 172–214Google Scholar
  25. 25.
    Fenwick E, O’Brien BJ, Briggs A. Cost-effectiveness acceptability curves: facts, fallacies and frequently asked questions. Health Econ 2004; 13 (5): 405–15PubMedCrossRefGoogle Scholar
  26. 26.
    Coast J. Who wants to know if their care is rationed? Views of citizens and service informants. Health Expect 2001; 4: 243–52PubMedCrossRefGoogle Scholar
  27. 27.
    Towse A, Pritchard C, Devlin N. Cost-effectiveness thresholds. London: Office of Health Economics, 2002Google Scholar
  28. 28.
    Lomborg B. Global crises, global solutions. Cambridge: Cambridge University Press, 2004CrossRefGoogle Scholar
  29. 29.
    Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ 1996; 5 (6): 513–24PubMedCrossRefGoogle Scholar
  30. 30.
    Fenwick E, Claxton K, Sculpher MJ, et al. Improving the efficiency and relevance of health technology assessment: the role of iterative decision analytic modelling. York: University of York, 2000Google Scholar
  31. 31.
    Shillcutt S, Morel C, Goodman C, et al. Cost-effectiveness of malaria diagnostic methods in sub-Saharan Africa in an era of combination therapy. Bull WHO 2008; 86 (2): 101–10PubMedGoogle Scholar
  32. 32.
    Tyagi V, Singh SK, Sawhney A, et al. Using gross national product to calculate acceptable immunisation costs: deploying cost-effectiveness calculations in reverse. Pharmacoeconomics 2003; 21 (7): 497–9PubMedCrossRefGoogle Scholar
  33. 33.
    Summers LH. Investing in the people. Pak Dev Rev 1992; 31 (4): 367–406PubMedGoogle Scholar
  34. 34.
    Coleman PG, Goodman CA, Mills A. Rebound mortality and the cost-effectiveness of malaria control: potential impact of increased mortality in late childhood following the introduction of insecticide treated nets. Trop Med Int Health 1999; 4 (3): 175–86PubMedCrossRefGoogle Scholar
  35. 35.
    Goodman CA, Coleman PG, Mills AJ. Cost-effectiveness of malaria control in sub-Saharan Africa. Lancet 1999; 354 (9176): 378–85PubMedCrossRefGoogle Scholar
  36. 36.
    Goodman CA, Coleman PG, Mills AJ. Changing the first line drug formalaria treatment: cost-effectiveness analysis with highly uncertain inter-temporal trade-offs. Health Econ 2001; 10 (8): 731–49PubMedCrossRefGoogle Scholar
  37. 37.
    Budke CM, Jiamin QIU, Qian W, et al. Economic effects of echinococcosis in a disease-endemic region of the Tibetan Plateau. Am J Trop Med Hyg 2005; 73 (1): 2–10PubMedGoogle Scholar
  38. 38.
    Caincross S, Valdmanis V. Water supply, sanitation, and hygiene promotion. In: Jamison DT, Breman JG, Measham AR, et al., editors. Disease control priorities in developing countries. New York: Oxford University Press and the World Bank, 2006Google Scholar
  39. 39.
    Walker D, Rheingans R. Cost-effectiveness of rotavirus vaccines. Exp Rev Pharmacoeconomics Outcomes Res 2005; 5 (5): 593–601CrossRefGoogle Scholar
  40. 40.
    Von Schirnding Y, Bruce N, Smith K, et al. Addressing the impact of household energy and indoor air pollution on the health of the poor: implications for policy action and intervention measures [working paper 12]. Geneva: World Health Organization Commission for Macroeconomics and Health, Working Group 5, 2001Google Scholar
  41. 41.
    Varley RC, Tarvid J, Chao DN. A reassessment of the costeffectiveness of water and sanitation interventions in programmes for controlling childhood diarrhoea. Bull WHO 1998; 76 (6): 617–31PubMedGoogle Scholar
  42. 42.
    Guyatt HL, Snow RW, Evans DB. Malaria epidemiology and economics: the effect of delayed immune acquisition on the cost-effectiveness of insecticide-treated bednets. Phil Trans Roy Soc B: Biol Sci 1999; 354 (1384): 827–35CrossRefGoogle Scholar
  43. 43.
    Listorti J, Doumani F. Energy and environmental health: a literature review and recommendations. Washington, DC: World Bank, 2001Google Scholar
  44. 44.
    Sachs J. Macroeconomics and health: investing in health for economic development. Geneva: World Health Organization, 2001Google Scholar
  45. 45.
    Jha P, Mills A. Improving health outcomes of the poor: the report of working group 5 of the Commission on Macroeconomics and Health. Geneva: World Health Organization, 2002Google Scholar
  46. 46.
    Simon J, Gray A, Duley L, Magpie Trial Collaborative Group. Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the Magpie trial. BJOG 2006; 11: 144–51CrossRefGoogle Scholar
  47. 47.
    Aggarwal R, Ghoshal UC, Naik SR. Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries. Natl Med J India 2002; 15 (6): 320–7PubMedGoogle Scholar
  48. 48.
    Dye C, Floyd K. Tuberculosis. In: Jamison DT, Breman JG, Measham AR, et al., editors. Disease control priorities in developing countries. New York: Oxford University Press and the World Bank, 2006Google Scholar
  49. 49.
    Briggs AH, Gray AM. Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess 1999; 3 (2): 1–134PubMedGoogle Scholar
  50. 50.
    Jha P, Bangoura O, Ranson K. The cost-effectiveness of forty health interventions in Guinea. Health Pol Plan 1998; 13 (3): 249–62CrossRefGoogle Scholar
  51. 51.
    Gerard K, Mooney G. QALY league tables: handle with care. Health Econ 1993; 2 (1): 59–64PubMedCrossRefGoogle Scholar
  52. 52.
    Birch S, Gafni A. Cost-effectiveness ratios: in a league of their own. Health Policy 1994; 28 (2): 133–41PubMedCrossRefGoogle Scholar
  53. 53.
    Drummond M, Torrance G, Mason J. Cost-effectiveness league tables: more harm than good? Soc Sci Med 1993; 37 (1): 33–40PubMedCrossRefGoogle Scholar
  54. 54.
    Laxminarayan R, Mills AJ, Breman JG, et al. Advancement of global health: key messages from the Disease Control Priorities Project. Lancet 2006; 367 (9517): 1193–208PubMedCrossRefGoogle Scholar
  55. 55.
    Sendi PP, Briggs AH. Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane. Health Econ 2001; 10 (7): 675–80PubMedCrossRefGoogle Scholar
  56. 56.
    WHO Investing in Health Research and Development. Report of the Ad Hoc committee on health research relating to future intervention options. Geneva: World Health Organization, 1996Google Scholar
  57. 57.
    Bobadilla JL, Cowley P, Musgrove P, et al. Design, content, and financing of an essential national package of health services. Washington, DC: World Bank, 1995Google Scholar
  58. 58.
    World Bank. World development indicators data query [online]. Available from URL: (http://ddp-ext.worldbank.org/ext/DDPQQ/member.do?method=getMembers&userid=1&queryId=135) [Accessed 2008 Oct 9]
  59. 59.
    Birch S, Gafni A. Information created to evade reality (ICER): things we should not look to for answers. Pharmacoeconomics 2006; 24 (11): 1121–31PubMedCrossRefGoogle Scholar
  60. 60.
    Birch S, Gafni A. Economics and the evaluation of health care programmes: generalisability of methods and implications for generalisability of results. Health Policy 2003; 64: 207–19PubMedCrossRefGoogle Scholar
  61. 61.
    Cohen JP. Cost-effectiveness and resource allocation [letter]. JAMA 2006; 295 (23): 2723PubMedCrossRefGoogle Scholar
  62. 62.
    Ssengooba F. Uganda’s minimum package for health care: rationing within the minimum? Health Policy Dev J 2003; 2 (1)Google Scholar
  63. 63.
    Devlin N, Ashton T, Cumming J. Rationing health care: how should the HFA proceed? N Z Med J 1999; 112 (1097): 369–70Google Scholar
  64. 64.
    Garber AM, Phelps CE. Economic foundations of costeffectiveness analysis. J Health Econ 1997; 16 (1): 1–31PubMedCrossRefGoogle Scholar
  65. 65.
    Weinstein MC. From cost-effectiveness ratios to resource allocation: where to draw the line? In: Sloan FA, editor. Valuing health care: costs, benefits, and effectiveness of pharmaceuticals and other medical technologies. New York: Cambridge University Press, 1995Google Scholar
  66. 66.
    Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Dec Making 2000; 20 (3): 332–42CrossRefGoogle Scholar
  67. 67.
    Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Ass J 1992; 146 (4): 473–81Google Scholar
  68. 68.
    Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13: 437–52PubMedCrossRefGoogle Scholar
  69. 69.
    IMTA. €80,000 per QALY is the limit. Institute of Medical Technology Assessment Newsletter, Netherlands 2006; 4 (1) [online]. Available from URL: (http://www.imta.nl/publications/imta_newsletter_4_1.pdf) [Accessed 2006 Oct 30]
  70. 70.
    Mills AJ, Shillcutt SD. Communicable diseases. In: Lomborg B, editor. Global crises, global solutions. Cambridge: Cambridge University Press, 2004: 62–111CrossRefGoogle Scholar
  71. 71.
    González-Pier E, Gutiárrez-Delgado C, Stevens G, et al. Health system reform in Mexico: priority setting for health interventions in Mexico’s system of social protection in health. Lancet 2006; 368: 1608–18PubMedCrossRefGoogle Scholar
  72. 72.
    Loomis C. Warren Buffett gives it away. Fortune 2006; 154 (1): 56–60PubMedGoogle Scholar
  73. 73.
    WHO. National health accounts: country information. Geneva: WHO [online]. Available from URL: (http://www.who.int/nha/country/en/) [Accessed 2009 Jan 20]
  74. 74.
    Bobadilla JL, Saxenian H. Designing an essential national health package. Finance Dev 1993; 30: 10–3Google Scholar
  75. 75.
    Addison T. Perspective paper 3.2. In: Lomborg B, editor. Global crises, global solutions. Cambridge: Cambridge University Press, 2004: 165–74Google Scholar
  76. 76.
    Appleton S. Perspective paper 7.2. In: Lomborg B, editor. Global crises, global solutions. Cambridge: Cambridge University Press, 2004: 435–42Google Scholar
  77. 77.
    Behrman JR, Alderman H, Hoddinott J. Malnutrition and hunger. In: Lomborg B, editor. Global crises, global solutions. Cambridge: Cambridge University Press, 2004: 363–420CrossRefGoogle Scholar
  78. 78.
    Schelling TC. Expert panel ranking. In: Lomborg B, editor. Global crises, global solutions. Cambridge: Cambridge University Press, 2004: 627–9Google Scholar
  79. 79.
    Stokey N. Expert panel ranking. In: Lomborg B, editor. Global crises, global solutions. Cambridge: Cambridge University Press, 2004: 639–44Google Scholar
  80. 80.
    Johansson PO. An introduction to modern welfare economics. Cambridge: Cambridge University Press, 1991CrossRefGoogle Scholar
  81. 81.
    Weaver M, Ndamobissi R, Kornfield R, et al. Willingness to pay for child survival: results of a national survey in Central African Republic. Soc Sci Med 1996; 43 (6): 985–98PubMedCrossRefGoogle Scholar
  82. 82.
    King Jr JT, Tsevat J, Lave JR, et al. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Dec Mak 2005; 25 (6): 605–6CrossRefGoogle Scholar
  83. 83.
    Cho-Min-Naing LS, Kamol-Ratanakul P, Saul AJ. Ex post and ex ante willingness to pay (WTP) for the ICTMalaria Pf/Pv test kit in Myanmar. Southeast Asian J Trop Med Public Health 2000; 31 (1): 104–11PubMedGoogle Scholar
  84. 84.
    Dong H, Kouyate B, Cairns J, et al. Willingness-to-pay for community-based insurance in Burkina Faso. Health Econ 2003; 12: 849–62PubMedCrossRefGoogle Scholar
  85. 85.
    Rheingans RD, Haddix AC, Messonnier ML, et al. Willingness to pay for prevention and treatment of lymphatic filariasis in Leogane, Haiti. Filaria J 2004; 3 (1): 2PubMedCrossRefGoogle Scholar
  86. 86.
    Jones-Lee M. Safety and the saving of a life, the economics of safety and physical risk. In: Layard R, Glaister S, editors. Cost-benefit analysis. Cambridge: Cambridge University Press, 2006: 290–318Google Scholar
  87. 87.
    Viscusi WK, Aldy JE. The value of a statistical life: a critical review of market estimates throughout the world. J Risk Uncertain 2003; 27 (1): 5–76CrossRefGoogle Scholar
  88. 88.
    Guria J, Leung J, Jones-Lee M, et al. The willingness to accept value of statistical life relative to the willingness to pay value: evidence and policy implications. Environmental Res Econ 2005; 32 (1): 113–27CrossRefGoogle Scholar
  89. 89.
    Whynes DK, Sach TH. WTP and WTA: do people think differently? Soc Sci Med 2007; 65 (5): 946–57PubMedCrossRefGoogle Scholar
  90. 90.
    Jamison D. Investing in health. In: Jamison DT, Breman JG, Measham AR, et al., editors. Disease control priorities in developing countries. New York: Oxford University Press and the World Bank, 2006Google Scholar
  91. 91.
    Evans DB. Perspective paper 2.1. In: Lomborg B, editor. Global crises, global solutions. Cambridge: Cambridge University Press, 2004: 115–23Google Scholar
  92. 92.
    Ryan M, Scott DA, Reeves C, et al. Eliciting public preferences for healthcare: a systematic review of techniques. Health Technol Assess 2001; 5 (5): 1–186PubMedGoogle Scholar
  93. 93.
    Onwujekwe O. Criterion and content validity of a novel structured haggling contingent valuation question format versus the bidding game and binary with follow-up format. Soc Sci Med 2004; 58 (3): 525–37PubMedCrossRefGoogle Scholar
  94. 94.
    Cropper ML, Lampietti JA, Haile M, et al. The value of preventing malaria in Tembien, Ethiopia [World Bank Policy Research working paper no. 2273]. Washington, DC: World Bank, 2001Google Scholar
  95. 95.
    Dolan P, Metcalfe R, Munro V, et al. Valuing lives and life years: anomalies, implications, and an alternative. Health Econ Pol Law 2008; 3: 277–300Google Scholar
  96. 96.
    Whittington D, Matsui-Santana O, Freiberger JJ, et al. Private demand for a HIV/AIDS vaccine: evidence from Guadalajara, Mexico. Vaccine 2002; 20 (19-20): 2585–91PubMedCrossRefGoogle Scholar
  97. 97.
    Mathiyazhagan K. Willingness to pay for rural health insurance through community participation in India. Int J Health Plann Mgmt 1998; 13: 47–67CrossRefGoogle Scholar
  98. 98.
    Dong H, Kouyate B, Cairns J, et al. Inequality in willingness-to-pay for community-based health insurance. Health Policy 2005; 72 (2): 149–56PubMedCrossRefGoogle Scholar
  99. 99.
    Bonu S, Rani M, Bishai D. Using willingness to pay to investigate regressiveness of user fees in health facilities in Tanzania. Health Policy Plan 2003; 18 (4): 370–82PubMedCrossRefGoogle Scholar
  100. 100.
    Habbani K, Groot W, Jelovac I. Household health-seeking behaviour in Khartoum, Sudan: the willingness to pay for public health services if these services are of good quality. Health Policy 2006; 75 (2): 140–58PubMedCrossRefGoogle Scholar
  101. 101.
    Mataria A, Giacaman R, Khatib R, et al. Impoverishment and patients’ ‘willingness’ and ‘ability’ to pay for improving the quality of health care in Palestine: an assessment using the contingent valuation method. Health Policy 2006; 75 (3): 312–28PubMedCrossRefGoogle Scholar
  102. 102.
    Xu K, Evans DB, Kawabata K, et al. Household catastrophic health expenditure: a multicountry analysis. Lancet 2003; 362 (9378): 111–7PubMedCrossRefGoogle Scholar
  103. 103.
    Cookson R. QALYs and the capability approach. Health Econ 2005; 14 (8): 817–29PubMedCrossRefGoogle Scholar
  104. 104.
    Loomes G. (How) can we value health, safety and the environment? J Econ Psychol 2006; 27 (6): 713–36CrossRefGoogle Scholar
  105. 105.
    King Jr JT, Tsevat J, Roberts MS. Positive association between current health and health values for hypothetical disease states. Med Decision Making 2004; 24 (4): 367–78CrossRefGoogle Scholar
  106. 106.
    Sloan FA, Viscusi KW, Chesson HW, et al. Alternative approaches to valuing intangible health losses: the evidence for multiple sclerosis. J Health Econ 1998; 17 (4): 475–97PubMedCrossRefGoogle Scholar
  107. 107.
    Muela SH, Mushi AK, Ribera JM. The paradox of the cost and affordability of traditional and government health services in Tanzania. Health Policy Plan 2000; 15 (3): 296–302PubMedCrossRefGoogle Scholar
  108. 108.
    Smith RD. The reliability of willingness to pay for changes in health status. Appl Health Econ Health Policy 2004; 3 (1): 35–8PubMedCrossRefGoogle Scholar
  109. 109.
    Huack K, Smith PC, Goddard M. The economics of priority setting for health care: a literature review. Washington, DC: International Bank for Reconstruction and Development, World Bank, 2003Google Scholar
  110. 110.
    Sassi F, Archard L, Le Grand J. Equity and the economic evaluation of healthcare. Health Technol Assess 2001; 5 (3): 1–138PubMedGoogle Scholar
  111. 111.
    Ottersen T, Mbilinyi D, Maestad O, et al. Distribution matters: equity considerations among health planners in Tanzania. Health Policy 2008; 85 (2): 218–27PubMedCrossRefGoogle Scholar
  112. 112.
    Le Grand J. Equity, health, and health care. Soc Justice Res 1987; 1 (3): 257–74CrossRefGoogle Scholar
  113. 113.
    Nord E. The relevance of health state after treatment in prioritizing between different patients. J Med Ethics 1993; 19: 37–42PubMedCrossRefGoogle Scholar
  114. 114.
    Nord E, Street A, Richardson J, et al. The significance of age and duration of effect in social evaluation of health care. Health Care Anal 1996; 4 (2): 103–11PubMedGoogle Scholar
  115. 115.
    Ubel PA, DeKay ML, Baron J, et al. Cost-effectiveness analysis in a setting of budget constraints: is it equitable? N Eng J Med 1996; 334 (18): 1174–7CrossRefGoogle Scholar
  116. 116.
    Dolan P. The measurement of individual utility and social welfare. J Health Econ 1998; 17: 39–52PubMedCrossRefGoogle Scholar
  117. 117.
    Johannesson M, Gerdtham U. A note on the estimation of the equity efficiency trade-off for QALYs. J Health Econ 1996; 15: 359–68PubMedCrossRefGoogle Scholar
  118. 118.
    Andersson F, Lyttkens C. Preferences for equity in health behind a veil of ignorance. Health Econ 1999; 8: 369–78PubMedCrossRefGoogle Scholar
  119. 119.
    Wagstaff A. QALYs and the equity-efficiency tradeoff. J Health Econ 1991; 10: 21–41PubMedCrossRefGoogle Scholar
  120. 120.
    Borghi J. Aggregation rules for cost-benefit analysis: a health economics perspective. Health Econ 2008; 17 (7): 863–75PubMedCrossRefGoogle Scholar
  121. 121.
    Musgrove P. Cost-effectiveness as a criterion for public spending: a reply to William Jack’s ‘second opinion’. Health Policy 2000; 54: 229–33PubMedCrossRefGoogle Scholar
  122. 122.
    Jack W. Public spending on health care: how are different criteria related? A second opinion. Health Policy 2000; 53: 61–7PubMedCrossRefGoogle Scholar
  123. 123.
    Robinson JS, Barth ACM, Feltes CH, et al. Economic impact model for the development of a statewide trauma system in Georgia. J Med Assoc Ga 2007; 96 (3): 10–3PubMedGoogle Scholar
  124. 124.
    Creese A, Floyd K, Alban A, et al. Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet 2002; 359 (9318): 1635–42PubMedCrossRefGoogle Scholar
  125. 125.
    Baltussen R. Priority setting of public spending in developing countries: do not try to do everything for everybody. Health Policy 2006; 78 (2-3): 149–56PubMedCrossRefGoogle Scholar
  126. 126.
    Baltussen R, ten Asbroek AHA, Koolman X, et al. Priority setting using multiple criteria: should a lung health programme be implemented in Nepal? Health Policy Plan 2007; 22: 178–85PubMedCrossRefGoogle Scholar
  127. 127.
    Baltussen R, Niessen L. Priority setting of health interventions: the need for multi-criteria decision analysis. Cost Eff Resour Alloc 2006; 4 (14): 1–9Google Scholar
  128. 128.
    Tantivess S, Walt G. Using cost-effectiveness analyses to inform policy: the case of antiretroviral therapy in Thailand. Cost Eff Resour Alloc 2006; 4: 21PubMedCrossRefGoogle Scholar
  129. 129.
    Makundi E, Kapiriri L, Norheim OF. Combining evidence and values in priority setting: testing the balance sheet method in a low-income country. BMC Health Serv Res 2007; 7: 152PubMedCrossRefGoogle Scholar
  130. 130.
    Birch S, Gafni A. The biggest bang for the buck or bigger bucks for the bang: the fallacy of the cost-effectiveness threshold. J Health Serv Res Policy 2006; 11 (1): 46–51PubMedCrossRefGoogle Scholar
  131. 131.
    Kapiriri L, Martin DK. A strategy to improve priority setting in developing countries. Health Care Anal 2007; 15: 159–67PubMedCrossRefGoogle Scholar
  132. 132.
    Fox-Rushby JA, Hanson K. Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy Plan 2001; 16 (3): 326–31PubMedCrossRefGoogle Scholar
  133. 133.
    Jamison DT, Shahid-Salles SA, Jamison J, et al. Incorporating deaths near the time of birth into estimates of the global burden of disease. In: Lopez AD, editor. Global burden of disease and risk factors. New York: World Bank Publications, 2006Google Scholar
  134. 134.
    Simon J, Petrou S, Gray A. The valuation of prenatal life in economic evaluations of perinatal interventions. Health Econ 2009: 18 (4): 487–94PubMedCrossRefGoogle Scholar
  135. 135.
    Bloom DE, Canning D, Jamison DT. Health, wealth and welfare. Finance Dev 2004; 41: 10–4Google Scholar
  136. 136.
    Lopez-Casanovas G, Rivera B, Currais L. Health and economic growth: findings and policy implications. Cambridge (MA): MIT Press, 2005Google Scholar
  137. 137.
    Sen A. Inequality re-examined. Cambridge (MA): Harvard University Press, 1992Google Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Samuel D. Shillcutt
    • 1
  • Damian G. Walker
    • 1
  • Catherine A. Goodman
    • 2
    • 3
  • Anne J. Mills
    • 3
  1. 1.Department of International HealthJohns Hopkins Bloomberg School of Public HealthBaltimoreUSA
  2. 2.Kenya Medical Research Institute/Wellcome Trust Research ProgrammeNairobiKenya
  3. 3.Department of Public Health & PolicyLondon School of Hygiene & Tropical MedicineLondonUK

Personalised recommendations